Physician profile
Glen E Johnson
NPI 1326157298
$1,402.45
in general payments reported to CMS, 2019-2025
16 companies · $33.78 in 2025
The $33.78 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $340 · 2021: $308 · 2022: $116 · 2023: $217 · 2024: $65.98 · 2025: $33.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $341.44 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $189.39 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $152.61 | 2023-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $142.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $138.76 | 2019-2023 | Spravato |
| Jazz Pharmaceuticals INC. | $122.62 | 2021-2022 | |
| Eisai INC. | $69.02 | 2020-2021 | |
| Almatica Pharma LLC | $52.98 | 2023 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $42.72 | 2022-2024 | Quviviq |
| Allergan, INC. | $37.95 | 2020 | |
| Lundbeck LLC | $24.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $22.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.63 | 2019 | |
| Merck Sharp & Dohme LLC | $19.05 | 2023 | Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.35 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.